Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.51 |
| ▸ | AHR | P35869 | 4/20 | 0.46 |
| ▸ | PRKDC | P78527 | 4/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.38 |
| ▸ | GABRE | P78334 | 1/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24274999 | 0.93 | AHR (0.49) | ALOX5AHRPRKDCHDAC8ERN1 | |
| SCHEMBL19398804 | 0.84 | ALOX5 (0.53) | ALOX5PRKDCHDAC8PIK3CDPIK3CB | |
| SCHEMBL22738104 | 0.81 | AHR (0.71) | ALOX5AHRPRKDCPIK3CDPIK3CB | |
| SCHEMBL24637019 | 0.81 | ERN1 (0.38) | ERN1PTPN1TNKS | |
| SCHEMBL16745220 | 0.79 | ALOX5 (0.55) | ALOX5AHRPRKDCHDAC8PIK3CD | |
| SCHEMBL15989894 | 0.79 | ALOX5 (0.55) | ALOX5AHRPRKDCHDAC8PIK3CD | |
| SCHEMBL30790120 | 0.79 | ALOX5 (0.55) | ALOX5AHRPRKDCHDAC8PIK3CD | |
| SCHEMBL16491694 | 0.79 | ALOX5 (0.55) | ALOX5AHRPRKDCHDAC8PIK3CD | |
| SCHEMBL18620516 | 0.78 | ALOX5 (0.51) | ALOX5AHRPRKDCHDAC8PIK3CD | |
| SCHEMBL21510808 | 0.78 | ALOX5 (0.55) | ALOX5AHRPRKDCHDAC8GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190326517-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2019-10-24 | — | — | US | disclosed |
| US-10446760-B2 | Organic compound, organic optoelectric diode, and display device | SAMSUNG SDI CO., LTD. (KR) | 2019-10-15 | — | — | US | disclosed |
| US-20160351820-A1 | ORGANIC COMPOUND, ORGANIC OPTOELECTRIC DIODE, AND DISPLAY DEVICE | SAMSUNG SDI CO., LTD. (KR) | 2016-12-01 | — | — | US | disclosed |
| US-20160351820-A1 | ORGANIC COMPOUND, ORGANIC OPTOELECTRIC DIODE, AND DISPLAY DEVICE | SAMSUNG SDI CO., LTD. (KR) | 2016-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190326517-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CYP1A1, CRY1, CYP1B1 | ALOX5 675/4885AHR 102/4885PRKDC 4466/4885 |
| US-10446760-B2 | Organic compound, organic optoelectric diode, and display device | OCIAD1, OXER1, OR10J3 | ALOX5 527/4885AHR 3603/4885PRKDC 3447/4885 |
| US-20160351820-A1 | ORGANIC COMPOUND, ORGANIC OPTOELECTRIC DIODE, AND DISPLAY DEVICE | OCIAD1, OXER1, OR10J3 | ALOX5 527/4885AHR 3603/4885PRKDC 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.